US Federal Senate Bill SB475

US Federal 2025-2026 Regular Session

• Introduced: 2/6/25
• Refer: 2/6/25

Caption

Alternatives to PAIN Act

Summary

SB 475, the “Alternatives to Prevent Addiction In the Nation Act” or “Alternatives to PAIN Act,” would change Medicare Part D rules for certain non-opioid pain management drugs beginning January 1, 2026. The bill defines a “qualifying non-opioid pain management drug” as an FDA-approved drug or biological product for postoperative or other acute pain that does not act on opioid receptors, has no therapeutically equivalent product sold in the U.S., and falls below a specified wholesale acquisition cost threshold. For those qualifying drugs, the bill would eliminate the Part D deductible and require plans to place the drug on the lowest cost-sharing tier, if any, for purposes of coinsurance and other cost-sharing. It also makes conforming changes for low-income subsidy beneficiaries so that the same favorable cost-sharing treatment applies under the low-income provisions of Part D. The bill further prohibits Medicare prescription drug plans and Medicare Advantage prescription drug plans from using step therapy or prior authorization for qualifying non-opioid pain management drugs. In practical terms, plans could not require a patient to try an opioid first, nor could they require advance plan approval before covering the drug. The bill’s impact would be to amend multiple sections of the Social Security Act governing Medicare Part D, creating a special coverage and utilization-management category for certain non-opioid pain treatments. It would affect Medicare Part D sponsors, Medicare Advantage plans with drug coverage, beneficiaries who need acute pain treatment, and manufacturers of eligible non-opioid pain drugs. The available context shows broad bipartisan sponsorship and no recorded votes or committee debate yet, suggesting generally favorable or at least noncontroversial initial reception. The main policy thrust is reducing barriers to non-opioid pain treatment and encouraging alternatives to opioids, so any contention would likely center on plan costs, formulary management, and how narrowly the qualifying-drug definition is drawn rather than on the bill’s overall goal.

Impact

The bill would amend sections 1860D-2, 1860D-4, and 1860D-14 of the Social Security Act to create special Medicare Part D treatment for qualifying non-opioid pain management drugs. It would remove the deductible, require the lowest cost-sharing tier, and bar step therapy and prior authorization for those drugs, thereby limiting plan design and utilization management for a narrow class of acute-pain medications.

Sentiment

The bill appears to have strong bipartisan support at introduction, with a long list of Republican and Democratic cosponsors. No committee transcript or vote record is available, but the sponsorship pattern suggests the measure is broadly viewed as a patient-access and opioid-alternative bill rather than a partisan proposal.

Contention

No specific objections are recorded in the available materials. Likely areas of debate, if any, would involve Medicare plan sponsors and insurers concerned about reduced formulary flexibility, higher costs, and the loss of step-therapy and prior-authorization tools, versus supporters who would emphasize improved access to non-opioid pain treatment and reduced reliance on opioids. The bill’s narrow definition of qualifying drugs may also be a point of discussion for manufacturers and advocates seeking broader coverage.